Chemq on the nose
Article Abstract:
Australia's biotechnology company Chemq is finding it difficult to float $20 million in its rights issue because of the contest from Imugene and Biodiem that are manufacturing same animal pharmaceutical items. The reasons for the drop in the share price of Chemq, and the variations among the companies' financial models, cost controls are analyzed.
Publisher: B R W Media
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2004
Biotechnology industry, Biotechnology industries
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Red-blooded
Article Abstract:
The reasons behind the increase in share price of CSL Ltd. over $35, and reporting sales profits of $160.1 million, are examined.
Publisher: B R W Media
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2005
Sales, profits & dividends, Biological products industry, Company sales and earnings, Company earnings/profit, CSL Ltd.
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: Australia, Securities, Company securities
Similar abstracts:
- Abstracts: On the nose. High - stakes player. Time to grow up: chief executives worldwide are tired of cutting costs. They want growth and plenty of it
- Abstracts: Knight in tarnished armor. Value added
- Abstracts: Value in the stockmarket. Frankly wonderful. Bourse v. bonds on inflation call
- Abstracts: The madness of the crowd returns. Future stock. Dollar fading fast
- Abstracts: Brand resurrection. Mother of invention. The big store braw
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.